Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

BACKGROUND: Tofacitinib is a Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA) and has been investigated for psoriasis (PsO). OBJECTIVES: This post hoc analysis examined baseline cardiovascular (CV) disease risk and its association with the occurrence of major adverse cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristensen, Lars E., Strober, Bruce, Poddubnyy, Denis, Leung, Ying-Ying, Jo, Hyejin, Kwok, Kenneth, Vranic, Ivana, Fleishaker, Dona L., Fallon, Lara, Yndestad, Arne, Gladman, Dafna D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909057/
https://www.ncbi.nlm.nih.gov/pubmed/36777695
http://dx.doi.org/10.1177/1759720X221149965

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909057/
https://www.ncbi.nlm.nih.gov/pubmed/36777695
http://dx.doi.org/10.1177/1759720X221149965

Ejemplares similares